REFERENCES
- Alfrey A C, LeGendre G R, Kaehny W D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294: 184–188
- Smith P S, McClure J. Localization of aluminum by histochemical and electron probe X-ray microanalytical techniques in bone tissue of cases of renal osteodystrophy. J Clin Pathol 1982; 35: 1283–1293
- O'Hare J A, Murnaghan D J. Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate. N Engl J Med 1982; 306: 654–656
- Fernandez-Martin J L, Canteros A, Alles A, Massari P, Cannata-Andia J. Aluminum exposure in chronic renal failure in iberoamerica at the end of the 1990s: overview and perspectives. Am J Med Sci 2000; 320: 96–99
- Burwen D R, Olsen S M, Bland L A, Arduino M J, Reid M H, Jarvis W R. Epidemic aluminum intoxication in hemodialysis patients traced to use of an aluminum pump. Kidney Int 1995; 48: 469–474
- Fournier A, Oprisiu R, Said S, et al. Invasive versus non-invasive diagnosis of renal bone disease. Curr Opin Nephrol Hypertens 1997; 6: 333–348
- D'Haese P C, Couttenye M M, Goodman W G, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminum-related bone disease, increased risk for aluminum toxicity, or aluminum overload. Nephrol Dial Transplant 1995; 10: 1874–1884
- D'Haese P C, Couttenye M M, De Broe M E. Diagnosis and treatment of aluminum bone disease. Nephrol Dial Transplant 1996; 11(Suppl 3)74–79
- Cannata J B, Suarez Suarez C, Cuesta V, et al. Gastrointestinal aluminum absorption: is it modulated by the iron-absorptive mechanism?. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 354–359
- Cannata J B, Olaizola I R, Gomez-Alonso C, Menendez-Fraga P, Alonso-Suarez M, Diaz-Lopez J B. Serum aluminum transport and aluminum uptake in chronic renal failure: role of iron and aluminum metabolism. Nephron 1993; 65: 141–146
- Huang J Y, Huang C C, Lim P S, Wu M S, Leu M L. Effect of body iron stores on serum aluminum level in hemodialysis patients. Nephron 1992; 61: 158–162
- Cannata J B, Fernandez-Martin J L, Diaz-Lopez B, et al. Influence of iron status in the response to the deferoxamine test. J Am Soc Nephrol 1996; 7: 135–139
- Harris W R, Berthon G, Day J P, et al. Speciation of aluminum in biological systems. J Toxicol Environ Health 1996; 48: 543–568
- Malluche H H, Monier-Faugere M C. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994; 4: 1631–1642
- Kaye M, Hodsman A B, Malynowsky L. Staining of bone for aluminum: use of acid solochrome azurine. Kidney Int 1990; 37: 1142–1147
- van Landeghem G F, D'Haese P C, Lamberts L V, et al. Low serum aluminum values in dialysis patients with increased bone aluminum levels. Clin Nephrol 1998; 50: 69–76
- Exley C, Burgess E, Day J P, Jeffery E H, Melethil S, Yokel R A. Aluminum toxicokinetics. J Toxicol Environ Health 1996; 48: 569–584
- Van Landeghem G F, D'Haese P C, Lamberts L V, De Broe M E. Competition of iron and aluminum for transferrin: the molecular basis for aluminum deposition in iron-overloaded dialysis patients?. Exp Nephrol 1997; 5: 239–245
- Boelaert J R, Locht M. Side-effects of desferrioxamine in dialysis patients. Nephrol Dial Trnasplant 1993; 1(suppl)43–46